Eli Lilly and Co. and Avidity Biosciences, Inc. have entered a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other indications.  The companies will leverage Avidity’s technology platform to progress new therapeutic approaches for clinical development and commercialization. Avidity’s platform seeks to combine the tissue selectivity of monoclonal antibodies and the precision of oli...